Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2021 / Cilt: 26 - Sayı: 3

What is the Effectiveness of Current COVID-19 Vaccines Against SARS-CoV-2 Variants? What to Know About the Need for Third Doses

Mevcut COVID-19 Aşılarının SARS-CoV-2 Varyantlarına Etkinliği Nasıl? Üçüncü Dozların Gerekliliği Hakkında Bilinmesi Gerekenler

Pages
361–368
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is also intended to shed light on what should be known about the necessity of third doses.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:SARS-CoV-2 genetic variants from alpha (first detected in the UK) to delta (discovered in India this spring) to lambda (currently Argentina, Brazil, Chile, Colombia, Ecuador, and Peru) have been emerging and circulating the world.
📊
Key Findings & Data:Also, these variants have raised concerns about the continued effectiveness of COVID-19 vaccines.
💡
Conclusion & Impact:It is also intended to shed light on what should be known about the necessity of third doses.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

SARS-CoV-2 genetic variants from alpha (first detected in the UK) to delta (discovered in India this spring) to lambda (currently Argentina, Brazil, Chile, Colombia, Ecuador, and Peru) have been emerging and circulating the world. Also, these variants have raised concerns about the continued effectiveness of COVID-19 vaccines. In this review, influential variants cause countries to review their vaccine strategies, create new vaccine programs, and accelerate existing vaccine studies. The effectiveness of currently available COVID-19 vaccines on variants is discussed. It is also intended to shed light on what should be known about the necessity of third doses.

Özet

SARS-CoV-2 genetik varyantlarından ‘Endişe uyandıran varyantlar’ alfadan (İlk olarak Birleşik Krallık’ta tespit edilmiştir.) deltaya (Hindistan’da tespit edilmiş ve tüm dünyada baskın varyant olmuştur.) ve ‘Dikkat edilmesi gereken varyantlar’ etadan lambdaya (şu anda Arjantin, Brezilya, Şili, Kolombiya, Ekvador, ve Peru’da) kadar ortaya çıkmakta ve tüm dünyayı dolaşmaktadır. Ayrıca bu varyantlar COVID-19 aşılarının devam eden etkinliği konusunda var olan endişeleri daha da arttırmaktadır. Bu derlemede tüm dünyada etkili olan, ülkelerin aşı stratejilerini gözden geçirip yeni aşı programları oluşturmasına ve mevcut aşı çalışmalarının hızlanmasına neden olan varyantlar ve halihazırda mevcut COVID-19 aşılarının varyantlara etkinliği irdelenmiştir. Ayrıca, üçüncü dozların gerekliliği hakkında bilinmesi gerekenlere ışık tutmak amaçlanmıştır.

🔖

Cite This Article

ÜNAL, S., AL, L. İ. R., SÖNMEZER, M. Ç. (2022). What is the Effectiveness of Current COVID-19 Vaccines Against SARS-CoV-2 Variants? What to Know About the Need for Third Doses. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 26 - Sayı: 3, 361–368. https://ajindex.com/articles/517087

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. World Health Organization Solidarity Vaccines Trial Expert Group. Draft Landscape and Tracker of COVID-19 Candidate Vaccines; WHO: Geneva, Switzerland, 2021
  2. Regulatory Affairs Professionals Society (RAPS). Craven J. COVID-19 Vaccine Tracker. Available from: https:// www.raps.org/news-and-articles/news-articles/2020/3/ covid-19-vaccine-tracker
  3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. NEJM 2020;383(27):2603-15
  4. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARSCoV-2 vaccine. N Engl J Med 2021;384:403-16
  5. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficay endpoint in the first Interim Analyses of the Phase 3 COVE Study, Nov 2020. Available from: https:// investors.modernatx.com/node/10316/pdf 6. World Health Organization (WHO). Tracking SARS-CoV-2 Available from:
  6. Public Health England. Investigation of Novel SARSCoV-2 Variant: Variant of Concern 202012/01 Technical Briefing 3. Accessed date: 08.05.2021. Available from: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/959360/ Variant_of_Concern_VOC_202012_01_Technical_Briefing_3.pdf
  7. Kershner I, Zimmer K. “Israel’s Vaccination Results Point a Way Out of Virus Pandemic,” New York Times, Apr 5, 2021
  8. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7). Lancet 2021;Feb 4 (preprint)
  9. Parsons L. Novavax’s COVID-19 vaccine ‘Highly’ effective against UK variant. Pharma Times, 15 Mar 2021. Available from: http://www.pharmatimes.com/news/ novavaxs_covid-19_vaccine_highly_effective_against_uk_variant_1365241 15
  10. Moderna. Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa. Moderna 25 Jan 2021. Available from: https://investors.modernatx. com/news-releases/news-releasedetails/moderna-covid-19-vaccine-retains-neutralizing-activity-against
  11. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 variants. NEJM 2021;385:187–9
  12. Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.